Exchange: NASDAQ·Updated 07:37 PM EST

CRBP News

News
all
press releases
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Has Average Target Price of $35.67 According to Analysts
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rati...
MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Has Average Target Price of $35.67 According to Analysts
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rati...
MarketBeat
More News
Capricor and Savara face Nov.22 FDA deadlines, while Beren Therapeutics awaits a Tuesday decision on Adrabetadex.
Stocktwits
Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
Zacks
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a company focused on oncology and obesity, said on Monday that it has appointed Leonardo Viana Nicacio as Chief Medical Officer...
Nasdaq News: Markets
Guggenheim upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday...
MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-corbus-pharmaceuticals-holdings-inc-stock...
MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving Average - Should You Sell...
MarketBeat
Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday...
MarketBeat
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...
MarketBeat
Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...
MarketBeat

Advertisement|Remove ads.